These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

596 related articles for article (PubMed ID: 30867316)

  • 1. Contribution of the Cytoplasmic Determinants of Vpu to the Expansion of Virus-Containing Compartments in HIV-1-Infected Macrophages.
    Leymarie O; Lepont L; Versapuech M; Judith D; Abelanet S; Janvier K; Berlioz-Torrent C
    J Virol; 2019 Jun; 93(11):. PubMed ID: 30867316
    [TBL] [Abstract][Full Text] [Related]  

  • 2. β-TrCP is dispensable for Vpu's ability to overcome the CD317/Tetherin-imposed restriction to HIV-1 release.
    Tervo HM; Homann S; Ambiel I; Fritz JV; Fackler OT; Keppler OT
    Retrovirology; 2011 Feb; 8():9. PubMed ID: 21310048
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The C-Terminal End of HIV-1 Vpu Has a Clade-Specific Determinant That Antagonizes BST-2 and Facilitates Virion Release.
    Sharma S; Jafari M; Bangar A; William K; Guatelli J; Lewinski MK
    J Virol; 2019 Jun; 93(11):. PubMed ID: 30867310
    [TBL] [Abstract][Full Text] [Related]  

  • 4. HIV-1 Vpu Antagonizes CD317/Tetherin by Adaptor Protein-1-Mediated Exclusion from Virus Assembly Sites.
    Pujol FM; Laketa V; Schmidt F; Mukenhirn M; Müller B; Boulant S; Grimm D; Keppler OT; Fackler OT
    J Virol; 2016 Aug; 90(15):6709-6723. PubMed ID: 27170757
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Membrane Anchoring by a C-terminal Tryptophan Enables HIV-1 Vpu to Displace Bone Marrow Stromal Antigen 2 (BST2) from Sites of Viral Assembly.
    Lewinski MK; Jafari M; Zhang H; Opella SJ; Guatelli J
    J Biol Chem; 2015 Apr; 290(17):10919-33. PubMed ID: 25759385
    [TBL] [Abstract][Full Text] [Related]  

  • 6. LC3C Contributes to Vpu-Mediated Antagonism of BST2/Tetherin Restriction on HIV-1 Release through a Non-canonical Autophagy Pathway.
    Madjo U; Leymarie O; Frémont S; Kuster A; Nehlich M; Gallois-Montbrun S; Janvier K; Berlioz-Torrent C
    Cell Rep; 2016 Nov; 17(9):2221-2233. PubMed ID: 27880899
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A cytoplasmic tail determinant in HIV-1 Vpu mediates targeting of tetherin for endosomal degradation and counteracts interferon-induced restriction.
    Kueck T; Neil SJ
    PLoS Pathog; 2012; 8(3):e1002609. PubMed ID: 22479182
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Filamin A Is Involved in HIV-1 Vpu-mediated Evasion of Host Restriction by Modulating Tetherin Expression.
    Dotson D; Woodruff EA; Villalta F; Dong X
    J Biol Chem; 2016 Feb; 291(8):4236-46. PubMed ID: 26742839
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Conserved residues within the HIV-1 Vpu transmembrane-proximal hinge region modulate BST2 binding and antagonism.
    Lukhele S; Cohen ÉA
    Retrovirology; 2017 Mar; 14(1):18. PubMed ID: 28288652
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Expression of HIV-1 Vpu leads to loss of the viral restriction factor CD317/Tetherin from lipid rafts and its enhanced lysosomal degradation.
    Rollason R; Dunstan K; Billcliff PG; Bishop P; Gleeson P; Wise H; Digard P; Banting G
    PLoS One; 2013; 8(9):e75680. PubMed ID: 24086611
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Role of the endosomal ESCRT machinery in HIV-1 Vpu-induced down-regulation of BST2/tetherin.
    Janvier K; Roy N; Berlioz-Torrent C
    Curr HIV Res; 2012 Jun; 10(4):315-20. PubMed ID: 22524180
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Activities of transmitted/founder and chronic clade B HIV-1 Vpu and a C-terminal polymorphism specifically affecting virion release.
    Jafari M; Guatelli J; Lewinski MK
    J Virol; 2014 May; 88(9):5062-78. PubMed ID: 24574397
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Vpu binds directly to tetherin and displaces it from nascent virions.
    McNatt MW; Zang T; Bieniasz PD
    PLoS Pathog; 2013; 9(4):e1003299. PubMed ID: 23633949
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Structural basis of HIV-1 Vpu-mediated BST2 antagonism via hijacking of the clathrin adaptor protein complex 1.
    Jia X; Weber E; Tokarev A; Lewinski M; Rizk M; Suarez M; Guatelli J; Xiong Y
    Elife; 2014 Apr; 3():e02362. PubMed ID: 24843023
    [TBL] [Abstract][Full Text] [Related]  

  • 15. HIV-1 Vpu's lipid raft association is dispensable for counteraction of the particle release restriction imposed by CD317/Tetherin.
    Fritz JV; Tibroni N; Keppler OT; Fackler OT
    Virology; 2012 Mar; 424(1):33-44. PubMed ID: 22222210
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tethered virions are intermediates in the assembly and release of HIV-1 particles.
    Karetnikov A; Suomalainen M
    Virology; 2010 Nov; 407(2):289-95. PubMed ID: 20850859
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Stimulation of NF-κB activity by the HIV restriction factor BST2.
    Tokarev A; Suarez M; Kwan W; Fitzpatrick K; Singh R; Guatelli J
    J Virol; 2013 Feb; 87(4):2046-57. PubMed ID: 23221546
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Differential Control of BST2 Restriction and Plasmacytoid Dendritic Cell Antiviral Response by Antagonists Encoded by HIV-1 Group M and O Strains.
    Bego MG; Cong L; Mack K; Kirchhoff F; Cohen ÉA
    J Virol; 2016 Nov; 90(22):10236-10246. PubMed ID: 27581991
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Vpu Exploits the Cross-Talk between BST2 and the ILT7 Receptor to Suppress Anti-HIV-1 Responses by Plasmacytoid Dendritic Cells.
    Bego MG; Côté É; Aschman N; Mercier J; Weissenhorn W; Cohen ÉA
    PLoS Pathog; 2015 Jul; 11(7):e1005024. PubMed ID: 26172439
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Vpu downmodulates two distinct targets, tetherin and gibbon ape leukemia virus envelope, through shared features in the Vpu cytoplasmic tail.
    Lucas TM; Janaka SK; Stephens EB; Johnson MC
    PLoS One; 2012; 7(12):e51741. PubMed ID: 23284757
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 30.